Rchr
J-GLOBAL ID：201601009904275310   Update date: Nov. 25, 2024

YAWARA KAWANO

カワノ ヤワラ | YAWARA KAWANO
Affiliation and department：
Kumamoto University University Hospital

About Kumamoto University University Hospital


Research field  (1)： Hematology and oncology
Research keywords  (6)： Flowcytometry ,  Waldenstrom Macroglobulinemia ,  Lymphoma ,  Amyloidosis ,  Plasma cell ,  Multiple Myeloma
Research theme for competitive and other funds  (2)：
  • 2020 - 2023 多発性骨髄腫におけるCD38経路を介した腫瘍細胞生存機構の解明と新規治療への応用
  • 2018 - 2021 Development of a novel multiple myeloma treatment targeting a plasma cell specific molecule
Papers (75)：
  • Kei Morikawa, Yasuhiro Izumiya, Seiji Takashio, Yawara Kawano, Tetsuya Oguni, Naoto Kuyama, Fumi Oike, Masahiro Yamamoto, Noriaki Tabata, Masanobu Ishii, et al. Early experience with daratumumab-containing regimens in patients with light-chain cardiac amyloidosis. Journal of Cardiology. 2024
  • Takumi Yamamoto, Arisu Furukawa, Yue Zhou, Nobuaki Kono, Shojiro Kitajima, Hiroto Ohguchi, Yawara Kawano, Shingo Ito, Norie Araki, Sumio Ohtsuki, et al. Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells. iScience. 2024
  • Nao NISHIMURA, Yawara KAWANO, Jun-ichirou YASUNAGA. Carfilzomib and dexamethasone in multiple myeloma patients refractory to anti-CD38 monoclonal antibodies. International Journal of Myeloma. 2024. 14. 5. 42-46
  • Shinya Endo, Nao Nishimura, Kosuke Toyoda, Yoshihiro Komohara, Joaquim Carreras, Hiromichi Yuki, Takafumi Shichijo, Shikiko Ueno, Niina Ueno, Shinya Hirata, et al. Decreased PU.1 expression in mature B cells induces lymphomagenesis. Cancer science. 2024
  • Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England journal of medicine. 2024
ｍore...
MISC (61)：
ｍore...
Lectures and oral presentations  (19)：
  • A lactate transporter, MCT1, may be a potential novel therapeutic target in multiple myeloma
    (臨床血液 2014)
  • Hypoxia induces immature phenotype and stem cell like transcriptional program in myeloma cells
    (臨床血液 2013)
  • Shikoninによる骨髄腫細胞へのprogrammed necrosisとapoptosis誘導
    (日本薬学会年会要旨集(CD-ROM) 2013)
  • CD138-low MM cells are of immature phenotype and with reduced lenalidomide (LEN) sensitivity
    (臨床血液 2012)
  • Low CD138 expression in myeloma cells, a potential indicator predicting poor prognosis
    (臨床血液 2011)
ｍore...
Education (2)：
  • 2009 - 2013 Kumamoto University Graduate School Medical Sciences
  • 2000 - 2006 Kumamoto University School of Medicine
Professional career (1)：
  • 医学博士 (熊本大学)
Work history (4)：
  • 2016/01 - 現在 Kumamoto University Hospital Dept of Hematology
  • 2013/08 - 2015/12 Dana-Farber Cancer Institute Dept of Medical Oncology
  • 2013/04 - 2013/08 Kumamoto University Hospital Dept of Hematology
  • 2008/04 - 2009/03 Kumamoto University Hospital Dept of Hematology
Awards (5)：
  • 2018/11 - Higo Foundation for promotion of Medical Education and Research Young Investigator Award of Higo Foundation for promotion of Medical Education and Research
  • 2017/03 - Kumamoto University School of Medicine Okukubo Memorial Fund for Medical Research
  • 2016/05 - THE JAPANESE SOCIETY OF MYELOMA Incentive award of the Japanese society of Myeloma
  • 2015/12 - THE AMERICAN SOCIETY OF HEMATOLOGY Abstract Achievement Award
  • 2013/10 - THE JAPANESE SOCIETY OF HEMATOLOGY Poster presentation award
Association Membership(s) (5)：
The American society of Hematology ,  日本臨床腫瘍学会 ,  THE JAPANESE SOCIETY OF MYELOMA ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE ,  THE JAPANESE SOCIETY OF HEMATOLOGY
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM